{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:16:18Z","timestamp":1781219778393,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T00:00:00Z","timestamp":1355443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s11136-012-0335-z","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T18:35:03Z","timestamp":1355423703000},"page":"2085-2094","source":"Crossref","is-referenced-by-count":19,"title":["Empirically driven definitions of \u201cgood,\u201d \u201cmoderate,\u201d and \u201cpoor\u201d levels of functioning in the treatment of schizophrenia"],"prefix":"10.1007","volume":"22","author":[{"given":"Haya","family":"Ascher-Svanum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanglin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,14]]},"reference":[{"key":"335_CR1","first-page":"27","volume":"6","author":"SR McGurk","year":"2004","unstructured":"McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004). Cognitive effects of olanzapine treatment in schizophrenia. Medscape General Medicine, 6, 27.","journal-title":"Medscape General Medicine"},{"key":"335_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0193-953X(02)00017-5","volume":"26","author":"J Lauriello","year":"2003","unstructured":"Lauriello, J., Lenroot, R., & Bustillo, J. R. (2003). Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatric Clinics of North America, 26, 191\u2013211.","journal-title":"Psychiatric Clinics of North America"},{"key":"335_CR3","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1176\/appi.ps.54.11.1499","volume":"54","author":"R Lenroot","year":"2003","unstructured":"Lenroot, R., Bustillo, J. R., Lauriello, J., & Keith, S. J. (2003). Integrated treatment of schizophrenia. Psychiatric Services, 54, 1499\u20131507.","journal-title":"Psychiatric Services"},{"key":"335_CR4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200826020-00005","volume":"26","author":"AG Awad","year":"2008","unstructured":"Awad, A. G., & Voruganti, L. N. (2008). The burden of schizophrenia on caregivers: a review. Pharmacoeconomics, 26, 149\u2013162.","journal-title":"Pharmacoeconomics"},{"key":"335_CR5","volume-title":"Quality of life and pharmacoeconomics: An introduction","author":"JA Cramer","year":"1998","unstructured":"Cramer, J. A., & Spilker, B. (1998). Quality of life and pharmacoeconomics: An introduction. Philadelphia, PA: Lippincott-Raven Publishers."},{"key":"335_CR6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","volume":"10","author":"DW Heinrichs","year":"1984","unstructured":"Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984). The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10, 388\u2013398.","journal-title":"Schizophrenia Bulletin"},{"key":"335_CR7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/oxfordjournals.schbul.a006869","volume":"27","author":"J Cramer","year":"2001","unstructured":"Cramer, J., Rosenheck, R., Xu, W., Henderson, W., Thomas, J., & Charney, D. (2001). Department of Veterans Affairs Cooperative Study Group on Clozapine in refractory schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin, 27, 227\u2013234.","journal-title":"Schizophrenia Bulletin"},{"key":"335_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.psychres.2008.09.004","volume":"170","author":"IA Lipkovich","year":"2009","unstructured":"Lipkovich, I. A., Deberdt, W., Csernansky, J. G., Buckley, P., Peuskens, J., Kollack-Walker, S., et al. (2009). Defining \u201cgood\u201d and \u201cpoor\u201d outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Research, 170, 161\u2013167.","journal-title":"Psychiatry Research"},{"key":"335_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCP.0b013e3181e69042","volume":"30","author":"SM Stahl","year":"2010","unstructured":"Stahl, S. M., Malla, A., Newcomer, J. W., Potkin, S. G., Weiden, P. J., Harvey, P. D., et al. (2010). A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Journal of Clinical Psychopharmacology, 30, 425\u2013430.","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"335_CR10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","volume":"79","author":"S Leucht","year":"2005","unstructured":"Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. R. (2005). What does the PANSS mean? Schizophrenia Research, 79, 231\u2013238.","journal-title":"Schizophrenia Research"},{"key":"335_CR11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.npp.1300093","volume":"28","author":"WB Bilker","year":"2003","unstructured":"Bilker, W. B., Brensinger, C., Kurtz, M. M., Kohler, C., Gur, R. C., Siegel, S. J., et al. (2003). Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology, 28, 773\u2013777.","journal-title":"Neuropsychopharmacology"},{"key":"335_CR12","unstructured":"Detke, H.C., Weiden, P.J., Llorca, P.M., Choukour, M., Watson, S.B., Brunner, E., et al. (2011). Open label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. Presented at the 13th International Congress on Schizophrenia Research, April 2011, Colorado Springs, Colorado, USA [Abstract] Schizophrenia Bulletin 37 (Supplement 1), 300."},{"key":"335_CR13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/oxfordjournals.schbul.a006935","volume":"28","author":"G Bryson","year":"2002","unstructured":"Bryson, G., Lysaker, P., & Bell, M. (2002). Quality of life benefits of paid work activity in schizophrenia. Schizophrenia Bulletin, 28, 249\u2013257.","journal-title":"Schizophrenia Bulletin"},{"key":"335_CR14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0924-9338(99)00231-X","volume":"14","author":"S Simon-Abbadi","year":"1999","unstructured":"Simon-Abbadi, S., Guelfi, J. D., & Ginestet, D. (1999). Psychometric qualities of the French version of the Heinrichs Quality of Life Rating Scale. European Psychiatry, 14, 386\u2013391.","journal-title":"European Psychiatry"},{"key":"335_CR15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(02)00240-8","volume":"113","author":"Y Kaneda","year":"2002","unstructured":"Kaneda, Y., Imakura, A., Fujii, A., & Ohmori, T. (2002). Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Research, 113, 107\u2013113.","journal-title":"Psychiatry Research"},{"key":"335_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psychres.2005.01.007","volume":"135","author":"M Ritsner","year":"2005","unstructured":"Ritsner, M., Kurs, R., Ratner, Y., & Gibel, A. (2005). Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Research, 135, 65\u201375.","journal-title":"Psychiatry Research"},{"key":"335_CR17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.schbul.a033484","volume":"26","author":"JA Cramer","year":"2000","unstructured":"Cramer, J. A., Rosenheck, R., Xu, W., Thomas, J., Henderson, W., & Charney, D. S. (2000). Quality of life in schizophrenia: A comparison of instruments. Schizophrenia Bulletin, 26, 659\u2013666.","journal-title":"Schizophrenia Bulletin"},{"key":"335_CR18","volume-title":"SF-36 health survey manual and interpretation guide","author":"JE Ware Jr","year":"1993","unstructured":"Ware, J. E., Jr, Snow, K. K., Kosinski, M., & Gandek, B. (1993). SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center."},{"key":"335_CR19","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware Jr","year":"2000","unstructured":"Ware, J. E., Jr. (2000). SF-36 health survey update. Spine, 25, 3130\u20133139.","journal-title":"Spine"},{"key":"335_CR20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00005650-199907000-00008","volume":"37","author":"SL Tunis","year":"1999","unstructured":"Tunis, S. L., Croghan, T. W., Heilman, D. K., Johnstone, B. M., & Obenchain, R. L. (1999). Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care, 37, 678\u2013691.","journal-title":"Medical Care"},{"key":"335_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.schres.2008.10.002","volume":"107","author":"L Kleinman","year":"2009","unstructured":"Kleinman, L., Lieberman, J., Dube, S., Mohs, R., Zhao, Y., Kinon, B., et al. (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research, 107, 275\u2013285.","journal-title":"Schizophrenia Research"},{"key":"335_CR22","unstructured":"Kind, P., Hardman, G., & Macran, S. (1999). UK Population Norms for EQ-5D. Discussion paper 172. Centre for Health Economics, University of York, York, 1\u201398."},{"key":"335_CR23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33, 337\u2013343.","journal-title":"Annals of Medicine"},{"key":"335_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0447.107.s416.6.x","volume":"416","author":"L Prieto","year":"2003","unstructured":"Prieto, L., Novick, D., Sacrist\u00e1n, J. A., Edgell, E. T., Alonso, J., & SOHO Study Group. (2003). A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica Supplement, 416, 24\u201329.","journal-title":"Acta Psychiatrica Scandinavica Supplement"},{"key":"335_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eurpsy.2006.08.004","volume":"22","author":"HH K\u00f6nig","year":"2007","unstructured":"K\u00f6nig, H. H., Roick, C., & Angermeyer, M. C. (2007). Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. European Psychiatry, 22, 177\u2013187.","journal-title":"European Psychiatry"},{"key":"335_CR26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-244X-11-87","volume":"11","author":"H Liu-Seifert","year":"2011","unstructured":"Liu-Seifert, H., Ascher-Svanum, H., Osuntokun, O., Jen, K. Y., & Gomez, J. C. (2011). Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BioMed Central Psychiatry, 11, 87.","journal-title":"BioMed Central Psychiatry"},{"key":"335_CR27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261\u2013276.","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl. 7","key":"335_CR28","first-page":"59","volume":"155","author":"SR Kay","year":"1989","unstructured":"Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The positive and negative syndrome scale (PANSS): Rationale and standardization. British Journal of Psychiatry, 155(Suppl. 7), 59\u201365.","journal-title":"British Journal of Psychiatry"},{"key":"335_CR29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/schbul\/16.3.537","volume":"16","author":"SR Kay","year":"1990","unstructured":"Kay, S. R., & Sevy, S. (1990). Pyramidal model of schizophrenia. Schizophrenia Bulletin, 16, 537\u2013545.","journal-title":"Schizophrenia Bulletin"},{"key":"335_CR30","volume-title":"Positive and negative syndromes in schizophrenia. Assessment and research","author":"SR Kay","year":"1991","unstructured":"Kay, S. R. (1991). Positive and negative syndromes in schizophrenia. Assessment and research. New York: Brunner\/Mazel."},{"key":"335_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0920-9964(99)00129-2","volume":"42","author":"C Lan\u00e7on","year":"2000","unstructured":"Lan\u00e7on, C., Auquier, P., Nayt, G., & Reine, G. (2000). Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 42, 231\u2013239.","journal-title":"Schizophrenia Research"},{"key":"335_CR32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eurpsy.2009.02.005","volume":"24","author":"M J\u00e4ger","year":"2009","unstructured":"J\u00e4ger, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L. G., et al. (2009). Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. European Psychiatry, 24, 501\u2013506.","journal-title":"European Psychiatry"},{"key":"335_CR33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2005.09.002","volume":"82","author":"EJ Oord Van den","year":"2006","unstructured":"Van den Oord, E. J., Rujescu, D., Robles, J. R., Giegling, I., Birrell, C., Buksz\u00e1r, J., et al. (2006). Factor structure and external validity of the PANSS revisited. Schizophrenia Research, 82, 213\u2013223.","journal-title":"Schizophrenia Research"},{"key":"335_CR34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2008.11.007","volume":"108","author":"D Novick","year":"2009","unstructured":"Novick, D., Haro, J. M., Suarez, D., Vieta, E., & Naber, D. (2009). Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Research, 108, 223\u2013230.","journal-title":"Schizophrenia Research"},{"key":"335_CR35","volume-title":"Classification and regression trees","author":"L Breiman","year":"1984","unstructured":"Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984). Classification and regression trees. Calif., USA: Wadsworth, Inc."},{"key":"335_CR36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbn171","volume":"35","author":"PD Harvey","year":"2009","unstructured":"Harvey, P. D., & Bellack, A. S. (2009). Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophrenia Bulletin, 35, 300\u2013306.","journal-title":"Schizophrenia Bulletin"},{"key":"335_CR37","unstructured":"Ritsner, M.S., Arbitman, M., Lisker, A., & Ponizovsky, A.M. (2011). Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Quality of Life Research Oct 2 [Epub ahead of print]."},{"key":"335_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1034\/j.1600-0447.2003.00072.x","volume":"107","author":"R Kilian","year":"2003","unstructured":"Kilian, R., Matschinger, H., Becker, T., & Angermeyer, M. C. (2003). A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatrica Scandinavica, 107, 351\u2013360.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"335_CR39","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1176\/appi.ajp.2008.07111713","volume":"165","author":"S Mohamed","year":"2008","unstructured":"Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J. A., & Keefe, R. S. (2008). Relationship of cognition and psychopathology to functional impairment in schizophrenia. American Journal of Psychiatry, 165, 978\u2013987.","journal-title":"American Journal of Psychiatry"},{"key":"335_CR40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.schres.2011.04.001","volume":"129","author":"S Brissos","year":"2011","unstructured":"Brissos, S., Dias, V. V., Balanz\u00e1-Martinez, V., Carita, A. I., & Figueira, M. L. (2011). Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophrenia Research, 129, 133\u2013136.","journal-title":"Schizophrenia Research"},{"key":"335_CR41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.psychres.2011.06.019","volume":"189","author":"M Erickson","year":"2011","unstructured":"Erickson, M., Jaafari, N., & Lysaker, P. (2011). Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia. Psychiatry Research, 189, 161\u2013165.","journal-title":"Psychiatry Research"},{"key":"335_CR42","unstructured":"Llorca, P.M., Blanc, O., Samalin, L., Bosia, M., Cavallaro, R. & on behalf of the EGOFORS Initiative (2011). Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry Jun. 29 [Epub ahead of print]."}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-012-0335-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-012-0335-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-012-0335-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T23:14:51Z","timestamp":1553642091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-012-0335-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,14]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s11136-012-0335-z","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,14]]}}}